MacroGenics Presents Results from SOPHIA Study
The company reported results from its Phase 3 SOPHIA study in patients with HER2-positive metastatic breast cancer.
Mustang Bio Announces Additional Clinical Data on MB-107
The company announced that updated Phase 1/2 clinical data for MB-107 was presented at the 61st American Society of Hematology...
Abeona Therapeutics to Initiate Phase 3 Clinical Trial of B-101
The company announced that the US Food and Drug Administration has removed its clinical hold on its Phase 3 clinical...
Akari Therapeutics Announces Phase 3 Trial Design
The company has announced the design of its Phase 3 pediatric trial in HSCT-TMA after an end-of-Phase 2 meeting with...
Cancer Genetics Reports Q3 Financial Results
Cancer Genetics has reported its Q3 strategic, financial and operating results for the third quarter ended September 30, 2019.
Anchiano Discontinues Phase 2 Codex Study
The company discontinued its Phase 2 Codex study evaluating the gene therapy inodiftagene vixteplasmid in bladder cancer.
CENTOGENE Signs Collaboration Agreement with Pfizer
The agreement will give Pfizer access to CENTOGENE's data repository for novel genetic and biochemical targets for therapies for rare...
